Form 4: SELLAS CDO's Tax Withholding on RSU Vesting

SELLAS Life Sciences Group's SVP, Chief Development Officer, Dragan Cicic, had 63,800 shares withheld for tax obligations related to RSU vesting.

Summary

• Dragan Cicic, the Senior Vice President and Chief Development Officer of SELLAS Life Sciences Group, Inc. (SLS), reported a change in beneficial ownership.
• On December 3, 2025, 63,800 shares of common stock were withheld by the company.
• This withholding was specifically to cover tax obligations associated with the vesting of Restricted Stock Units (RSUs) held by Mr. Cicic.
• The deemed price for the shares withheld was $1.5 per share.
• Following this transaction, Mr. Cicic beneficially owns 257,805 shares of SELLAS Life Sciences Group common stock.

Sentiment

Score: 6

Explanation: The transaction is a routine tax withholding related to RSU vesting, which is a neutral to slightly positive event as it indicates compensation vesting. It is not a discretionary sale by the insider and does not suggest any negative sentiment from the executive.

Positives

• The transaction represents a routine vesting of Restricted Stock Units (RSUs), indicating that executive compensation plans are active and functioning.
• The withholding of shares for tax purposes is a non-discretionary event, not a market sale initiated by the insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report is a standard disclosure for executive compensation and does not directly reflect broader industry trends. It is a common occurrence across various industries when Restricted Stock Units vest for executives.

Comparison to Industry Standards

• The practice of withholding shares to cover tax obligations upon RSU vesting is a standard and widely adopted method of managing executive compensation in publicly traded companies across all sectors.
• This transaction is consistent with typical executive compensation structures involving equity awards, similar to those seen in biotechnology and pharmaceutical companies of comparable size to SELLAS Life Sciences Group.

Related Party Transactions

• The transaction involves the company (Issuer) and an executive (Reporting Person) in a standard compensation-related event, specifically the withholding of shares to cover tax obligations arising from RSU vesting.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and has a negligible direct impact on current share value or company operations. The underlying RSU vesting would have been accounted for in compensation planning.
• Employees: Indicates that the company's equity compensation plans for executives are active and vesting as scheduled.

Key Dates

Recommendation

This Form 4 filing details a routine tax withholding transaction related to the vesting of Restricted Stock Units for an executive. It is not a discretionary sale and does not provide new information that would fundamentally alter the investment thesis for SELLAS Life Sciences Group. Therefore, a 'hold' recommendation is appropriate as this event is neutral to the company's operational or financial performance.

Keywords

SELLAS Life Sciences Group, SLS, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Dragan Cicic, Beneficial Ownership